Independent scientists have said that BPC-157 appears promising in lab studiesbut with major caveats
, BPC-157
Discussion High Pyroglutamic acid indicates a disturbed GSH homeostasis in symptomatic TTR-V30M gene carriers In a recent study, we demonstrated that the formation of the aggregation-prone NNTTR species, initially discovered in plasma from TTR-V30M gene carriers [21], is promoted by the formation of a disulfide bridge [22]

Hypoparathyroidism affectsnumerous systems in the body and is associated with a range of short-term symptoms and long-term complications.2,4,6 Brain Symptoms of anxiety and depression Fatigue Cognitive impairment, brain fog Central nervous system Seizures Calcifications Parkinsonism or dystonia Lungs Laryngospasm Kidneys** Nephrocalcinosis Kidney stones Chronic kidney disease Peripheralnervous system Paresthesia Muscle cramps Tetany Eyes Cataracts Papilledema Teeth Altered tooth morphology Heart Cardiac arrhythmias Hypocalcaemia associated dilated cardiomyopathy Skin Dry skin Pustular psoriasis Brittle nails and prone to onycholysis Coarse, thin hair Musculoskeletal Myopathy Spondyloarthropathy * Germany, Austria, France, Spain, Portugal, Italy, United Kingdom, Switzerland, Belgium, Netherlands, Luxembourg, Denmark, Finland, Iceland, Norway, Sweden, U.S., LATAM/Canada, CEE/Eurasia, MENA, ANZ, Israel, South Korea, Japan, China

The published preclinical literature uses weight-adjusted rodent dosing that doesn't translate cleanly to fixed human protocols, so researchers extrapolate